A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae148 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Carol M Kao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Hepatitis E, Immunoglobulin G. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Emory University School of Medicine, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Establishing the safety and immunogenicity of a hepatitis E virus vaccine in multiple populations could facilitate broader access and prevent maternal and infant mortality.
Methods
We conducted a phase 1, randomized, double-blinded, placebo-controlled (4:1 vaccine to placebo) trial of 30 µg HEV-239 (Hecolin, Xiamen Innovax Biotech Company Limited, China) administered intramuscularly in healthy US adults aged 18–45 years. Participants were vaccinated on days 1, 29, and 180. Participants reported solicited local and systemic reactions for 7 days following vaccination and were followed through 12 months after enrollment for safety and immunogenicity (IgG, IgM).
Results
Solicited local and systemic reactions between treatment and placebo group were similar and overall mild. No participants experienced serious adverse events related to HEV-239. All participants receiving HEV-239 seroconverted at 1 month following the first dose and remained seropositive throughout the study. HEV-239 elicited a robust hepatitis E IgG response that peaked 1 month following the second dose (geometric mean concentration [GMC], 6.16; 95% confidence interval [CI], 4.40–8.63), was boosted with the third dose (GMC, 11.50; 95% CI, 7.90–16.75) and persisted through 6 months.
Conclusions
HEV-239 is safe and elicits a durable immune response through at least 6 months after the third dose in healthy US adults. Clinical Trials Registration NCT03827395.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Hope Clinic, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
- Xiamen Innovax Biotech Company Limited, Xiamen, China.
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
- The Emmes Company, LLC, Rockville, Maryland, USA.
ORCID-Profile: Christina A Rostad, Lauren E Nolan, Satoshi Kamidani, Nadine Rouphael
Förderung
- Emory University School of Medicine
- NIAID NIH HHS
- NIH HHS
- Children's Healthcare of Atlanta
- National Institute of Allergy and Infectious Diseases
- Georgia Research Alliance
- National Institutes of Health
- Children’s Healthcare of Atlanta
Zitieren
APA
Kao, C. M., Rostad, C. A., Nolan, L. E., Peters, E., Kleinhenz, J., Sherman, J. D., Tippett, A., Shih, J. W. K., Yildirim, I., Agbakoba, V., Beresnev, T., Ballou, C., Kamidani, S., Karmali, V., Natrajan, M., Scherer, E. M., Rouphael, N., & Anderson, E. J. (2024). A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae148
Vancouver
Kao CM, Rostad CA, Nolan LE, Peters E, Kleinhenz J, Sherman JD, et al. A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae148
BibTeX
@article{Kao2024,
author = {Kao, Carol M and Rostad, Christina A and Nolan, Lauren E and Peters, Etza and Kleinhenz, Jennifer and Sherman, Jacob D and Tippett, Ashley and Shih, J Wai Kuo and Yildirim, Inci and Agbakoba, Vivien and Beresnev, Tatiana and Ballou, Cassandra and Kamidani, Satoshi and Karmali, Vinit and Natrajan, Muktha and Scherer, Erin M and Rouphael, Nadine and Anderson, Evan J},
title = {A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae148}
}
EUVIMED